

# **The TLR5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens**

Rhonda H. Wilson<sup>1,3</sup>, Shuichiro Maruoka<sup>1,3</sup>, Gregory S. Whitehead<sup>1</sup>, Julie F. Foley<sup>1</sup>, Gordon P. Flake<sup>1</sup>, Michelle L. Sever<sup>1</sup>, Darryl C. Zeldin<sup>1</sup>, Monica Kraft<sup>2</sup>, Stavros Garantziotis<sup>1</sup>, Hideki Nakano<sup>1</sup> & Donald N. Cook<sup>1</sup>


<sup>1</sup>Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709, USA, and <sup>2</sup>Duke Asthma, Allergy and Airway Center, Duke University Medical Center, Durham, NC 27710

<sup>3</sup>contributed equally to this work


**Supplementary Table 1.** Allergen and endotoxin content of HDEs.

Sample #	Derp1 (ng/g)	Derf1 (ng/g)	Derp/Derf2 (ng/g)	Feld1 (ng/g)	Canf1 (ng/g)	Ratn1 (ng/g)	Blag2 (ng/g)	Alta1 (ng/g)	LPS (EU/g)
1	74.6	34	94	n.d.	n.d.	n.d.	n.d.	n.d.	16,557
2	21.5	n.d.	52.5	n.d.	n.d.	28.8	n.d.	n.d.	18,778
3	89.2	n.d.	24.2	n.d.	n.d.	4.6	n.d.	n.d.	165
4	98	99.2	37.5	2,375.3	n.d.	4.6	n.d.	14.3	8,744
5	4,141.1	n.d.	3,842.1	30.9	44.1	6.2	403.8	n.d.	38,077
6	30.4	38.5	82.9	n.d.	27.1	n.d.	228.3	n.d.	11,766
7	1,776.2	49.5	1872	n.d.	130.45	n.d.	361.4	8.6	29,508


**Supplementary Table 1.** Allergen and endotoxin content of HDEs. Levels of the indicated allergens were measured by a multiplex assay. Shown are values present in dry house dust, as determined from dilutions of the extracts (see online methods). Der p, *Dermatophagoides pteronissinus* with protease activity; Feld, *Felis domesticus*, Canf, *Canis familiaris*; Blag, *Blattella germanica*; Ratn, *Rattus norvegicus*; Alta, *Alternaria alternata*; n.d., not detected.




**Supplementary Figure 1: Instillation of microbial products alone does not lead to allergic inflammation.** (a) Airway inflammation in mice receiving airway instillations of 25 ng, 125 ng or 625 ng microbial product (▲). 1250 ng of sFLA was also tested. The scale on the Y axis is the same as that for Fig. 1 to allow ready comparison between the two sets of data. Mean levels of the indicated leukocyte subsets  $\pm$  s.e.m. in BALF following a single OVA challenge are shown. Results shown are data from a single experiment.  $n = 5$  mice per group. (b) Induction of allergic responses to OVA using ultra-pure (u.p.) LPS or rFLA as adjuvants in C57BL/6 and BALB/c mice.




**Supplementary Figure 2: FLA primes allergic airway disease.** (a,b) Allergic responses in mice previously sensitized with (a) sFLA-OVA or (b) rFLA-OVA and challenged by OVA aerosol on seven consecutive days. Shown are mean values  $\pm$  s.e.m. of leukocytes in the airway, and airway resistance for intubated mice inhaling air (baseline), or aerosols of PBS containing the indicated concentrations of methacholine.  $n \geq 8$  mice/group. \*  $P < 0.01$  ( $t$  test) for differences between the indicated groups and mice sensitized and challenged with OVA only. (c) Gating strategy for live CD4<sup>+</sup> lymphocytes, using forward and side scatter (left), viability exclusion dye (middle), and staining for the CD4 and CD8 antigens.




**Supplementary Figure 3: *Tlr5*<sup>-/-</sup> mice develop allergic inflammation following sensitization with LPS-OVA.** Mean numbers  $\pm$  s.e.m. of inflammatory leukocytes in WT, *Tlr4*<sup>-/-</sup> and *Tlr5*<sup>-/-</sup> mice following allergic sensitization to OVA using as an adjuvant.  $n = 5 - 9$  for LPS-OVA treated groups,  $n = 4$  for negative control groups.



**Supplementary Figure 4: *Nlr4* is dispensable for FLA-mediated allergic sensitization through the airway.** Mean numbers ± s.e.m. of the indicated leukocyte subsets in BALF following a single OVA challenge. Data are from two experiments. *n* = 9 for sFLA-OVA treated mice, *n* = 4 for negative control groups.




**Supplementary Figure 5: Requirement of *Tlr5* expression on cell compartments for FLA-mediated allergic sensitization through the airway.** (a) *Tlr5* expression in select cell subsets prepared from the lung. Values are shown relative to CD103<sup>+</sup> dendritic cells (DC). AM, alveolar macrophages; AEC, airway epithelial cells (b) Reconstitution of irradiated recipient mice with donor bone marrow. Shown are representative flow plots for T cells and pulmonary macrophages from an irradiated WT CD45.1 mouse receiving WT CD45.2 marrow. Similar reconstitution levels were seen for other genotypes. (c) Function of *Cd11c-Myd88* transgene. CD11c<sup>+</sup> cells were prepared from lungs of the indicated mouse strains and treated *ex vivo* with LPS or FLA. TNF- $\alpha$  in cell supernatants were analyzed by ELISA.



**Supplementary Figure 6: Role of FLA as an environmental adjuvant.** (a) Western blot of multiple HDEs probed with a different anti-FLA antibody than that used in Fig.4b. (b) Cytokines in lungs of mice following HDE-OVA sensitization and OVA challenge.  $n = 7 - 10$  mice/group for HDE-OVA sensitizations, 4 per group for OVA only sensitizations. (c) Mean levels  $\pm$  s.e.m. of inflammatory leukocytes in BALF (left) and AHR (right) are shown for mice sensitized and challenged with HDE#4 (top) and HDE#5 (bottom). ( $n = 5 - 12$  mice/group). (d) Mean levels  $\pm$  s.e.m. of inflammatory leukocytes in BALF and of AHR are shown for cockroach antigen-sensitized and -challenged mice.  $n = 5 - 12$  mice/group.





**Supplementary Figure 7. Titers of antibodies to microbial products in asthmatic and non-asthmatic subjects. (a) Antibodies to FLA from *P. aeruginosa*. (b) Antibodies to LPS from *E. coli*.**

## ONLINE SUPPLEMENTARY METHODS

**Flow cytometry.** After blocking, surface antigens were stained using antibodies against mouse CD4 (clone RM4-5; BD Pharmingen) and CD8 $\alpha$  (clone 5H10; Caltag) or the appropriate isotype control. Dead cells were stained with Fixable Viability Dye eFluor® 780 (eBioscience) and excluded from analysis. Intracellular staining was done using antibodies against IL-13 (clone eBio13A; eBioscience) and IL-17A (clone TC11-18H10; BD Pharmingen).

**Heat-killed *Pseudomonas aeruginosa*-mediated sensitization to OVA.** We used PA01, a widely-used strain of *P. aeruginosa*, and PA01 $\Delta$ *fliC*, a mutant strain that lacks the flagellin-encoding *fliC* gene. The bacteria were grown overnight in Luria Bertoni broth, diluted 100-fold, transferred to fresh medium and grown for another 3 h. Bacterial counts were inferred from OD<sub>600nm</sub>, based on previous empirical data, and confirmed by plating of an aliquot of the culture for colony counting on the following day. Bacteria were centrifuged at 7000 rpm for 3 m, suspended in PBS, and incubated for 1 h at 56° C to kill the organisms, which were then centrifuged once more and resuspended in PBS. For allergic sensitizations, mice received various numbers of heat-killed bacteria together with 100  $\mu$ g OVA on days 0 and 7. For challenge, the mice were exposed to an aerosol of 1% OVA for 1 h on day 14.

**Analysis of airway inflammation, cytokines, and IgE.** Measurements of IL-4, IL-5, IL-17 in the BALF were assessed at 4 h post-challenge, using a commercial multiplexed fluorescent bead-based immunoassay (Bio-Rad Laboratories, Hercules, CA), according to the manufacturers' instructions. IL-13 was measured in supernatants of whole lung and lymph node cultures by an enzyme-linked immunosorbent assay (ELISA) using an anti-IL-13 antibody (eBioscience). TNF-

$\alpha$  in CD11c<sup>+</sup> cell supernatants was measured by ELISA (Biolegend), and serum IgE by ELISA (BD Bioscience).

**Isolation and culture of alveolar type II cells.** Lungs were perfused and instilled with 1.5 ml of dispase II (1.5 U/ml) (Roche) via the trachea, which was immediately closed with a ligature. Intact lungs were removed and incubated in culture tubes with an additional 2 ml of dispase II for 45 minutes at 37° C for digestion. After incubation, lungs were minced in a solution of Dulbecco's modified Eagle's medium (DMEM; Invitrogen), 25 mM HEPES (Sigma), 1% penicillin/streptomycin and 100U/ml DNase I (Sigma), then filtered through a 70  $\mu$ M cell strainer and incubated in Mouse IgG (Jackson, ImmunoResearch Laboratories, Inc.) coated plates for two hours at 37° C. Non-adherent cells were removed, washed and re-suspended in DMEM with 10% fetal bovine serum (FBS; certified, Invitrogen), 25 mM HEPES, 1% penicillin/streptomycin and 10 ng/ml keratinocyte growth factor (Sigma). Cells were cultured at an approximate density of  $2.5 \times 10^5$  cells/cm<sup>2</sup> in plates pre-coated with 30  $\mu$ g/ml bovine collagen I (Invitrogen) and 10  $\mu$ g/ml fibronectin (EMD4biosciences) at 37° C in an atmosphere of 5% CO<sub>2</sub>. Media was changed after the first day of culture and every two days thereafter until cells reached confluence.

**Isolation/culture of pulmonary dendritic cells and macrophages.** CD11c<sup>+</sup> DCs were fractionated into their CD11b<sup>+</sup> and CD103<sup>+</sup> subsets by flow cytometry-based cell sorting as previously described<sup>1</sup> and analyzed for *tlr5* expression by qPCR. For TNF- $\alpha$  analysis, CD11c<sup>+</sup> cells were isolated by a magnetic bead-based cell sorting system (Miltenyi) using a biotin-conjugated antibody against mouse CD11c (clone HL3; BD Pharmingen). Cells were cultured in

200  $\mu$ l of RPMI with 10% FBS (certified, Invitrogen), 50  $\mu$ M  $\beta$ -mercaptoethanol and penicillin streptomycin at a density of  $1 \times 10^5$  cells/well in a 96-well U-bottom plate (BD Biosciences).

**Human studies.** Non-smoking volunteers underwent a comprehensive screening protocol to define asthma and atopy phenotypes. Atopy was defined as having seasonal symptoms requiring medications and a positive skin-prick to house dust mite and at least 3 other aeroallergens. Asthmatic subjects had mild-moderate disease as defined by NHLBI EPR3 guidelines (<http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf>).

## LITERATURE CITED

- 1 Nakano, H. *et al.* Pulmonary CD103(+) dendritic cells prime Th2 responses to inhaled allergens. *Mucosal Immunol*, doi:10.1038/mi.2011.47 (2011).